Overcoming adherence issues in ulcerative colitis

Gastroenterology and Hepatology

Volumn 3, Issue 10, 2007, Pages 795-799

  Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

Author keywords

5 ASA; Adherence; Convenience; Ulcerative colitis

Indexed keywords

ANTIOXIDANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIALDA; MESALAZINE; SALAZOSULFAPYRIDINE; SALOFALK GRANU STIX; SCAVENGER; SULFAPYRIDINE; UNCLASSIFIED DRUG;

CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; DELAYED DRUG RELEASE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; ENTERITIS; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT SATISFACTION; PHYSICIAN; QUESTIONNAIRE; RELAPSE; REVIEW; RISK REDUCTION; TABLET; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 35948999316     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut. 2000;46:336-343.
2. Schmidt C, Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol. 2005;51:127-145.
3. Kovvali G, Das KM. Molecular mimicry may contribute to pathogenesis of ulcerative colitis. FEBS Lett. 2005;579:2261-2266.
4. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol. 2004;11:195-204.
5. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
6. Qureshi AJ, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev. 2005;57:281-302.
7. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357-369.
8. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl 5):V1-16.
9. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;102:43-49.
10. Riley SA, Mani V, Goodman MJ, Lucas S. Why do patients with ulcerative colitis relapse? Gut. 1990;31:179-183.
11. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-336.
12. Kane SV, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
13. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorecral cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-1183.
14. Eaden J, Abrams K, Ekbom A, et al. Colorecral cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000;14:145-153.
15. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-2933.
16. Bernstein CN, Ediger JP, Graff LA, et al. The Manitoba IBD cohort study: assessing the nature of medication adherence. Gastroenterology. 2006;130(4 suppl 2):Abstract W1167.
17. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-585.
18. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1-10.
19. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544.
20. Davis TC, Wolf MS, Bass PF III, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med. 2006;145:887-894.
21. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-550.
22. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesaiazine extended-release formulation. Aliment Pharmacol Ther. 2003;17:395-402.
23. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95-102.
24. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled phase III studies. Gastroenterology. 2006;130(4 suppl 2):A-484. Abstract T1148.
25. Hanauer S, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine 4.8g/day (800mg rablet) versus 2.4g/day (400mg tablet) for treatment of moderately active ulcerative colitis: combined analysis of two randomised, double-blind, controlled trials. Gastroenterology. 2005;128:A74-A75. Abstract 492.
26. Hanauer S, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005;100:2478-2485.
27. Pentasa once daily in ulcerative colitis for maintenance of remission. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00209300?order=3. Accessed 23 April 2007.
28. Kane SV, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170-173.
29. Wong JM, Wei SC. Efficacy of Pentasa tablets for the trearment of inflammatory bowel disease. J Formos Med Assoc. 2003;102:613-619.
30. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. SPD476, a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naïve: an analysis of pooled data from two phase III studies. Gastroenterology. 2007;130(4 suppl 2):A-482. Abstract T1139.